AIMS: The ability of mesenchymal stem cells (MSCs) to heal the chronically injured heart remains controversial. Here we tested the hypothesis that autologous MSCs can be safely injected into a chronic myocardial infarct scar, reduce its size, and improve ventricular function. METHODS AND RESULTS: Female adult Göttingen swine (n = 15) underwent left anterior descending coronary artery balloon occlusion to create reproducible ischaemia-reperfusion infarctions. Bone-marrow-derived MSCs were isolated and expanded from each animal. Twelve weeks post-myocardial infarction (MI), animals were randomized to receive surgical injection of either phosphate buffered saline (placebo, n = 6), 20 million (low dose, n = 3), or 200 million (high dose, n = 6) autologous MSCs in the infarct and border zone. Injections were administered to the beating heart via left anterior thoracotomy. Serial cardiac magnetic resonance imaging was performed to evaluate infarct size, myocardial blood flow (MBF), and left ventricular (LV) function. There was no difference in mortality, post-injection arrhythmias, cardiac enzyme release, or systemic inflammatory markers between groups. Whereas MI size remained constant in placebo and exhibited a trend towards reduction in low dose, high-dose MSC therapy reduced infarct size from 18.2 +/- 0.9 to 14.4 +/- 1.0% (P = 0.02) of LV mass. In addition, both low and high-dose treatments increased regional contractility and MBF in both infarct and border zones. Ectopic tissue formation was not observed with MSCs. CONCLUSION: Together these data demonstrate that autologous MSCs can be safely delivered in an adult heart failure model, producing substantial structural and functional reverse remodelling. These findings demonstrate the safety and efficacy of autologous MSC therapy and support clinical trials of MSC therapy in patients with chronic ischaemic cardiomyopathy.
AIMS: The ability of mesenchymal stem cells (MSCs) to heal the chronically injured heart remains controversial. Here we tested the hypothesis that autologous MSCs can be safely injected into a chronic myocardial infarct scar, reduce its size, and improve ventricular function. METHODS AND RESULTS: Female adult Göttingen swine (n = 15) underwent left anterior descending coronary artery balloon occlusion to create reproducible ischaemia-reperfusion infarctions. Bone-marrow-derived MSCs were isolated and expanded from each animal. Twelve weeks post-myocardial infarction (MI), animals were randomized to receive surgical injection of either phosphate buffered saline (placebo, n = 6), 20 million (low dose, n = 3), or 200 million (high dose, n = 6) autologous MSCs in the infarct and border zone. Injections were administered to the beating heart via left anterior thoracotomy. Serial cardiac magnetic resonance imaging was performed to evaluate infarct size, myocardial blood flow (MBF), and left ventricular (LV) function. There was no difference in mortality, post-injection arrhythmias, cardiac enzyme release, or systemic inflammatory markers between groups. Whereas MI size remained constant in placebo and exhibited a trend towards reduction in low dose, high-dose MSC therapy reduced infarct size from 18.2 +/- 0.9 to 14.4 +/- 1.0% (P = 0.02) of LV mass. In addition, both low and high-dose treatments increased regional contractility and MBF in both infarct and border zones. Ectopic tissue formation was not observed with MSCs. CONCLUSION: Together these data demonstrate that autologous MSCs can be safely delivered in an adult heart failure model, producing substantial structural and functional reverse remodelling. These findings demonstrate the safety and efficacy of autologous MSC therapy and support clinical trials of MSC therapy in patients with chronic ischaemic cardiomyopathy.
Authors: Karl H Schuleri; Andrew J Boyle; Marco Centola; Luciano C Amado; Robert Evers; Jeffrey M Zimmet; Kristine S Evers; Katherine M Ostbye; Diana G Scorpio; Joshua M Hare; Albert C Lardo Journal: Comp Med Date: 2008-12 Impact factor: 0.982
Authors: Philippe Menasché; Ottavio Alfieri; Stefan Janssens; William McKenna; Hermann Reichenspurner; Ludovic Trinquart; Jean-Thomas Vilquin; Jean-Pierre Marolleau; Barbara Seymour; Jérôme Larghero; Stephen Lake; Gilles Chatellier; Scott Solomon; Michel Desnos; Albert A Hagège Journal: Circulation Date: 2008-02-19 Impact factor: 29.690
Authors: Karl H Schuleri; Luciano C Amado; Andrew J Boyle; Marco Centola; Anastasios P Saliaris; Matthew R Gutman; Konstantinos E Hatzistergos; Behzad N Oskouei; Jeffrey M Zimmet; Randell G Young; Alan W Heldman; Albert C Lardo; Joshua M Hare Journal: Am J Physiol Heart Circ Physiol Date: 2008-02-29 Impact factor: 4.733
Authors: Martin Breitbach; Toktam Bostani; Wilhelm Roell; Ying Xia; Oliver Dewald; Jens M Nygren; Jochen W U Fries; Klaus Tiemann; Heribert Bohlen; Juergen Hescheler; Armin Welz; Wilhelm Bloch; Sten Eirik W Jacobsen; Bernd K Fleischmann Journal: Blood Date: 2007-05-04 Impact factor: 22.113
Authors: Vasileios Karantalis; Darcy L DiFede; Gary Gerstenblith; Si Pham; James Symes; Juan Pablo Zambrano; Joel Fishman; Pradip Pattany; Ian McNiece; John Conte; Steven Schulman; Katherine Wu; Ashish Shah; Elayne Breton; Janice Davis-Sproul; Richard Schwarz; Gary Feigenbaum; Muzammil Mushtaq; Viky Y Suncion; Albert C Lardo; Ivan Borrello; Adam Mendizabal; Tomer Z Karas; John Byrnes; Maureen Lowery; Alan W Heldman; Joshua M Hare Journal: Circ Res Date: 2014-02-24 Impact factor: 17.367
Authors: Adam R Williams; Konstantinos E Hatzistergos; Benjamin Addicott; Fred McCall; Decio Carvalho; Viky Suncion; Azorides R Morales; Jose Da Silva; Mark A Sussman; Alan W Heldman; Joshua M Hare Journal: Circulation Date: 2012-12-05 Impact factor: 29.690